FANAPT (iloperidone) 

Self-Administration - oral

Diagnosis considered for coverage:
  • Schizophrenia - Indicated for the treatment of adults with schizophrenia.

Coverage Criteria:

For diagnosis of Schizophrenia:

  • Dose does not exceed 12 mg twice daily (24 mg/day); AND

  • Inadequate response, intolerance, or contraindication to two of the following:

    • Aripiprazole
    • Olanzapine
    • Quetiapine IR/ER
    • Risperidone
    • Clozapine
    • Ziprasidone
    • Paliperidone
    • Asenapine
Coverage Duration:
  • Initial: 1 year

Authorization is not covered for the following:
  • The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information:
  • Drug Interactions:
    • The dose of Fanapt should be reduced in patients who co-administered a strong CYP2D6 or CYP3A4 inhibitor
Policy Updates:
  • 02/15/2022 – New policy approved by P&T
References:
  1. Fanapt prescribing information. Vanda Pharmaceuticals, Inc. Washington, D.C. January 2016.

Last review date: February 15, 2022

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone